NYSE:ENZ

Enzo Biochem Competitors

$3.36
-0.10 (-2.89 %)
(As of 04/12/2021 11:21 AM ET)
Add
Compare
Today's Range
$3.34
Now: $3.36
$3.38
50-Day Range
$2.75
MA: $3.26
$4.08
52-Week Range
$1.80
Now: $3.36
$4.85
Volume1,724 shs
Average Volume1.22 million shs
Market Capitalization$162.05 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89

Competitors

Enzo Biochem (NYSE:ENZ) Vs. CELC, CNTG, PROG, XGN, OPGN, and ANPC

Should you be buying ENZ stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Enzo Biochem, including Celcuity (CELC), Centogene (CNTG), Progenity (PROG), Exagen (XGN), OpGen (OPGN), and AnPac Bio-Medical Science (ANPC).

Enzo Biochem (NYSE:ENZ) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Enzo Biochem and Celcuity, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzo Biochem0000N/A
Celcuity00203.00

Celcuity has a consensus target price of $27.00, indicating a potential upside of 8.70%. Given Celcuity's higher probable upside, analysts clearly believe Celcuity is more favorable than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Celcuity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzo Biochem-24.36%-27.05%-14.76%
CelcuityN/A-52.57%-49.69%

Insider and Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 18.6% of Celcuity shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 43.5% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Enzo Biochem and Celcuity's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$76.02 million2.13$-28,520,000.00N/AN/A
CelcuityN/AN/A$-7,360,000.00($0.72)-34.50

Celcuity has lower revenue, but higher earnings than Enzo Biochem.

Risk & Volatility

Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Summary

Celcuity beats Enzo Biochem on 6 of the 11 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Enzo Biochem and Centogene, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzo Biochem0000N/A
Centogene00503.00

Centogene has a consensus target price of $20.00, indicating a potential upside of 63.27%. Given Centogene's higher probable upside, analysts clearly believe Centogene is more favorable than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Centogene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzo Biochem-24.36%-27.05%-14.76%
CentogeneN/AN/AN/A

Insider and Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 15.8% of Centogene shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Enzo Biochem and Centogene's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$76.02 million2.13$-28,520,000.00N/AN/A
Centogene$54.64 million4.45$-23,360,000.00($1.46)-8.39

Centogene has lower revenue, but higher earnings than Enzo Biochem.

Risk & Volatility

Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Centogene has a beta of -2.25, indicating that its stock price is 325% less volatile than the S&P 500.

Summary

Centogene beats Enzo Biochem on 7 of the 12 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and Progenity (NASDAQ:PROG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Enzo Biochem and Progenity, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzo Biochem0000N/A
Progenity10402.60

Progenity has a consensus price target of $8.60, suggesting a potential upside of 122.22%. Given Progenity's higher possible upside, analysts plainly believe Progenity is more favorable than Enzo Biochem.

Earnings and Valuation

This table compares Enzo Biochem and Progenity's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$76.02 million2.13$-28,520,000.00N/AN/A
ProgenityN/AN/AN/AN/AN/A

Progenity has lower revenue, but higher earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Progenity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzo Biochem-24.36%-27.05%-14.76%
ProgenityN/AN/AN/A

Insider & Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 17.1% of Progenity shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by insiders. Comparatively, 80.6% of Progenity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Progenity beats Enzo Biochem on 6 of the 8 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider & Institutional Ownership

60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 29.2% of Exagen shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by insiders. Comparatively, 48.9% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Enzo Biochem and Exagen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzo Biochem0000N/A
Exagen00503.00

Exagen has a consensus price target of $24.25, suggesting a potential upside of 50.43%. Given Exagen's higher possible upside, analysts plainly believe Exagen is more favorable than Enzo Biochem.

Earnings and Valuation

This table compares Enzo Biochem and Exagen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$76.02 million2.13$-28,520,000.00N/AN/A
Exagen$40.39 million5.06$-12,040,000.00($8.46)-1.91

Exagen has lower revenue, but higher earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Exagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzo Biochem-24.36%-27.05%-14.76%
Exagen-39.49%-29.10%-17.88%

Summary

Exagen beats Enzo Biochem on 6 of the 11 factors compared between the two stocks.

Enzo Biochem (NYSE:ENZ) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

60.4% of Enzo Biochem shares are held by institutional investors. Comparatively, 2.3% of OpGen shares are held by institutional investors. 9.4% of Enzo Biochem shares are held by insiders. Comparatively, 0.4% of OpGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, OpGen has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Enzo Biochem and OpGen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzo Biochem0000N/A
OpGen00203.00

OpGen has a consensus price target of $5.50, suggesting a potential upside of 113.18%. Given OpGen's higher possible upside, analysts clearly believe OpGen is more favorable than Enzo Biochem.

Earnings & Valuation

This table compares Enzo Biochem and OpGen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$76.02 million2.13$-28,520,000.00N/AN/A
OpGen$3.50 million28.21$-12,450,000.00($6.90)-0.37

OpGen has lower revenue, but higher earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and OpGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzo Biochem-24.36%-27.05%-14.76%
OpGen-586.99%-154.05%-68.88%

Summary

Enzo Biochem beats OpGen on 7 of the 12 factors compared between the two stocks.

AnPac Bio-Medical Science (NASDAQ:ANPC) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Earnings and Valuation

This table compares AnPac Bio-Medical Science and Enzo Biochem's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnPac Bio-Medical Science$1.56 million39.20$-14,520,000.00($1.62)-3.37
Enzo Biochem$76.02 million2.13$-28,520,000.00N/AN/A

AnPac Bio-Medical Science has higher earnings, but lower revenue than Enzo Biochem.

Analyst Recommendations

This is a summary of current recommendations and price targets for AnPac Bio-Medical Science and Enzo Biochem, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnPac Bio-Medical Science0000N/A
Enzo Biochem0000N/A

Insider and Institutional Ownership

0.0% of AnPac Bio-Medical Science shares are held by institutional investors. Comparatively, 60.4% of Enzo Biochem shares are held by institutional investors. 9.4% of Enzo Biochem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares AnPac Bio-Medical Science and Enzo Biochem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnPac Bio-Medical ScienceN/AN/AN/A
Enzo Biochem-24.36%-27.05%-14.76%

Summary

AnPac Bio-Medical Science beats Enzo Biochem on 6 of the 9 factors compared between the two stocks.


Enzo Biochem Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CELC
Celcuity
1.2$24.84-13.0%$265.42 millionN/A-29.22Analyst Report
Gap Up
Centogene logo
CNTG
Centogene
1.2$12.25-0.4%$244.29 million$54.64 million-8.39
Progenity logo
PROG
Progenity
1.8$3.87-0.0%$233.18 millionN/A0.00
Exagen logo
XGN
Exagen
1.6$16.12-1.4%$207.03 million$40.39 million-1.31
OpGen logo
OPGN
OpGen
1.3$2.58-3.5%$102.17 million$3.50 million-1.27Analyst Downgrade
AnPac Bio-Medical Science logo
ANPC
AnPac Bio-Medical Science
0.7$5.46-5.7%$64.63 million$1.56 million-3.37Gap Up
Biocept logo
BIOC
Biocept
1.2$4.33-6.2%$61.65 million$5.53 million-1.07
Miragen Therapeutics logo
MGEN
Miragen Therapeutics
0.9$15.66-6.7%$61.20 million$4.46 million-1.47Gap Up
PMD
Psychemedics
0.8$7.00-0.6%$38.53 million$37.68 million-10.14
Cancer Genetics logo
CGIX
Cancer Genetics
0.6$4.02-4.0%$16.42 million$7.30 million-1.94
AMS
American Shared Hospital Services
0.1$2.62-1.1%$15.09 million$20.60 million-26.20
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.